undamentalytics Newsletter
Sign in

Ultralife Corp key statistics and ratios

In fiscal 2025, Ultralife Corp had return on equity of -4.5% and a net margin of -3.1%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin−6.0%−3.7%−1.5%−1.6%−1.2%−3.2%3.8%4.3%8.9%28.6%4.9%4.9%−0.2%−0.1%4.5%3.8%−3.1%−3.5%
Return on equity−11.8%−8.1%−2.8%−2.2%−1.3%−2.9%4.2%5.2%10.4%27.1%4.9%4.6%−0.2%−0.1%6.0%4.9%−4.5%−5.0%
Return on assets—−5.4%−1.9%−1.6%−1.0%−2.4%3.4%4.2%8.4%22.9%3.9%3.7%−0.2%−0.1%4.2%3.2%−2.7%−3.0%
Effective tax rate—−2.8%26.0%———9.8%2.7%−21.7%—21.5%24.1%——21.4%22.8%——
R&D as % of revenue6.1%5.2%6.3%7.1%7.4%8.0%7.3%7.2%5.5%5.2%6.4%5.5%6.9%5.4%4.7%5.0%5.4%6.3%
SG&A as % of revenue19.1%15.6%17.1%21.3%22.1%23.3%18.6%18.7%17.6%16.7%15.9%16.3%18.1%16.8%14.0%14.6%15.4%16.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $216m
Short-term assets $107mLonger-term assets $109m
What it owes, and who funded it · $216m
Short-term liabilities $37mLonger-term liabilities $46mShareholders' equity $133m
  • Short-term assets cover short-term liabilities $107m of assets due within a year against $37m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $107m short-term assets against $46m of longer-dated liabilities.
  • More cash than debt $7m of cash against $45m of debt.
  • Debt below 40% of shareholders' equity Debt is 34% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 16% to 34% over five years.
  • A year's operating cash flow covers at least 20% of debt $5m of operating cash flow against $45m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Ultralife Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

42 /100

Weak moat

How hard Ultralife's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 7 / 20

    Cash operating profit has been a median 6.6% of total assets over 10 years.

  • Pricing power 9 / 20

    Gross margin has been a median 26.3%, moving by 2.8 percentage points (standard deviation) across 10 years.

  • Durability 0 / 20

    Operating margin has been a median 5.5%; its worst year was -4.5%.

  • Cash conversion 10 / 20

    Free cash flow was positive in 8 of 10 years, at a median 4.4% of revenue.

  • Discipline 16 / 20

    The diluted share count rose 3.2% over five years; stock-based pay has been a median 0.6% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ULBI vs WBXEOSE vs ULBINRGV vs ULBIFCEL vs ULBI

More: Electrical Components & Equipment stocks compared, Industrials sector, rankings of US companies

Figures from Ultralife Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ultralife Corp.